Genmab — November 2016
-
As you know, we are also focused on augmenting our portfolio with external opportunities, particularly in the field of oncology. However, our interest in partnerships and potential acquisitions is not limited to oncology, and we are considering opportunities where there is strong science and where we see the possibility of developing a truly differentiated product
-
Discipline has both components to it. There are a number of things that I think are probably too early for us to take part in. There are a number of things that I think are just overpriced. And so it's been a combination of those two things looking backward. Going forward, we'll have to see what makes sense for us and where we're willing to go to bring in new products.
-
Yep skulle de ikke allerede have haft en deal ud over Hiv-dealen? De snuser og snuser og render forvirret rundt og råber op om hvor dyrt det er at købe teknologi ude i byen, sidst jeg kiggede kostede det også kassen at gå på restaurant i stedet for at mixe noget biksemad sammen. Enten må de ansætte forskere og selv stå for udvikling og grundforskning eller også må de købe sig til det. Tik tak tik tak konkurrenterne haler ind på dem. Gad vide om Genmab er lidt for dyr når det kommer til stykket?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind